QPI-1007

QPI-1007 is an experimental drug from the group of RNAi therapeutics for the treatment of non-arteritic anterior ischemic optic neuropathy .

properties

QPI-1002 is a RNA applied to the mRNA of caspase 2 binds and RNA interference to a gene knockdown of Caspase 2 leads. It was in phase 3 clinical trials in 2017 . It is applied by injection into the vitreous body .

Individual evidence

1. ^ ^{A b} Jens Kurreck: Molecular Medicine. John Wiley & Sons, 2016, ISBN 978-3-527-33189-5 , p. 323.
2. ^ R. Titze-de-Almeida, C. David, SS Titze-de-Almeida: The Race of 10 Synthetic RNAi-Based Drugs to the Pharmaceutical Market. In: Pharmaceutical research. Volume 34, Number 7, July 2017, pp. 1339-1363, doi : 10.1007 / s11095-017-2134-2 , PMID 28389707 .

This article is about a health issue. It is not used for self-diagnosis and does not replace a diagnosis by a doctor. Please note the information on health issues !